In summary, this study clearly elucidates that LINC00460 promotes CRC immune escape through the LINC00460/miR-186-3p/MYC feedback loop, thereby enhancing the initiation and progression of CRC tumors. Targeted inhibition of LINC00460 may reduce the abundance of downstream MYC, CD47 and PD-L1 molecules, thereby inhibiting CRC tumor development and improving patient survival. Here, CD274 is linked to neoplasm.